Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPBWR1 | P48145 | 10/20 | 0.56 |
| ▸ | KISS1R | Q969F8 | 2/20 | 0.55 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.54 |
| ▸ | IL23R | Q5VWK5 | 3/20 | 0.53 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.53 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.52 |
| ▸ | ECE1 | P42892 | 1/20 | 0.52 |
| ▸ | GLP1R | P43220 | 1/20 | 0.52 |
| ▸ | MUS81 | Q96NY9 | 1/20 | 0.52 |
| ▸ | PTH1R | Q03431 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL677586 | 1.00 | NPBWR1 (0.56) | NPBWR1KISS1ROPRD1IL23RRXFP1 | |
| SCHEMBL30198266 | 0.97 | NPBWR1 (0.60) | NPBWR1IL23RRXFP1PTH1R | |
| SCHEMBL30874406 | 0.95 | NPBWR1 (0.57) | NPBWR1KISS1ROPRD1IL23RRXFP1 | |
| SCHEMBL29370686 | 0.94 | NPBWR1 (0.56) | NPBWR1KISS1ROPRD1IL23RRXFP1 | |
| SCHEMBL15849869 | 0.93 | NPBWR1 (0.55) | NPBWR1KISS1ROPRD1IL23RRXFP1 | |
| SCHEMBL30253514 | 0.93 | NPBWR1 (0.60) | NPBWR1IL23RRXFP1PRMT1 | |
| SCHEMBL31614451 | 0.92 | NPBWR1 (0.63) | NPBWR1IL23RRXFP1 | |
| SCHEMBL29396822 | 0.91 | NPBWR1 (0.61) | NPBWR1IL23RRXFP1PTH1R | |
| SCHEMBL2194373 | 0.90 | KISS1R (0.57) | NPBWR1KISS1RIL23R | |
| SCHEMBL31743243 | 0.90 | KISS1R (0.58) | NPBWR1KISS1RECE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4345104-B1 | METHOD FOR PREPARING LIRAGLUTIDE | BACHEM HOLDING AG (CH) | 2024-08-28 | — | — | EP | claimed |
| US-20240247042-A1 | GLUCAGON LIKE PEPTIDE COMPOUNDS | NOVARTIS AG (CH) | 2024-07-25 | — | — | US | claimed |
| EP-4380962-A1 | PROCESS FOR THE PREPARATION OF SEMAGLUTIDE | MSN Laboratories Private Limited, R&D Center (IN) | 2024-06-12 | — | — | EP | claimed |
| WO-2023012709-A1 | AN IMPROVED PROCESS FOR FMOC SYNTHESIS OF SEMAGLUTIDE | USV PRIVATE LIMITED (IN) | 2023-02-09 | — | — | WO | claimed |
| WO-2023012829-A1 | PROCESS FOR THE PREPARATION OF SEMAGLUTIDE | MSN LABORATORIES PRIVATE LIMITED, R&D CENTER (IN) | 2023-02-09 | — | — | WO | claimed |
| EP-3864032-B1 | PROCESS FOR THE MANUFACTURE OF GLP-1 ANALOGUES | FRESENIUS KABI IPSUM S R L (IT) | 2022-11-30 | — | — | EP | claimed |
| US-20220041680-A1 | PROCESS FOR THE MANUFACTURE OF GLP-1 ANALOGUES | Fresenius Kabi Ipsum S.R.L. (IT) | 2022-02-10 | — | — | US | claimed |
| US-12497644-B2 | Subtilisin variants and their use | Fresenius Kabi Ipsum S.R.L. (IT) | 2025-12-16 | — | — | US | disclosed |
| US-20250206798-A1 | INSULIN CONJUGATES | SANOFI SA (FR) | 2025-06-26 | — | — | US | disclosed |
| WO-2025093774-A1 | GLUCAGON-LIKE PEPTIDE 1 AGONISTS | Constructive Biology Limited (GB) | 2025-05-08 | — | — | WO | disclosed |
| CN-118561901-A | Compound containing bis ((siloxy) phenyl) methane structure and preparation method and application thereof | 南京工业大学 | 2024-08-30 | — | — | CN | disclosed |
| CN-118271420-A | GLP-1 analogue purification method | 江苏汉邦科技股份有限公司 | 2024-07-02 | — | — | CN | disclosed |
| US-20240150423-A1 | GLP-1 ANALOGUE-MODIFIED DIMERS WITH DIFFERENT CONFIGURATIONS, PREPARATION METHOD THEREOF, AND APPLICATION THEREOF IN TREATMENT OF TYPE II DIABETES | Nanjing Finepeptide Biopharmaceutical Co.,Ltd (CN) | 2024-05-09 | — | — | US | disclosed |
| WO-2023105497-A1 | SYNTHESIS OF GLP-1 ANALOGUES | ANTHEM BIOSCIENCES PVT. LTD. (IN) | 2023-06-15 | — | — | WO | disclosed |
| US-11396533-B2 | Process for the manufacture of GLP-1 analogues | Fresenius Kabi Ipsum S.R.L. (IT) | 2022-07-26 | — | — | US | disclosed |
| US-20220195004-A1 | METHOD FOR PREPARING TARGET POLYPEPTIDE BY MEANS OF RECOMBINATION AND SERIES CONNECTION OF FUSED PROTEINS | PEG-BIO BIOPHARM CO., LTD. (CHONGQING) (CN) | 2022-06-23 | — | — | US | disclosed |
| US-20220041680-A1 | PROCESS FOR THE MANUFACTURE OF GLP-1 ANALOGUES | Fresenius Kabi Ipsum S.R.L. (IT) | 2022-02-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240150423-A1 | GLP-1 ANALOGUE-MODIFIED DIMERS WITH DIFFERENT CONFIGURATIONS, PREPARATION METHOD THEREOF, AND APPLICATION THEREOF IN TREATMENT OF TYPE II DIABETES | GLP1R, IAPP, GCG | NPBWR1 431/4885KISS1R 1181/4885OPRD1 2268/4885 |
| US-20220041680-A1 | PROCESS FOR THE MANUFACTURE OF GLP-1 ANALOGUES | GLP1R, IAPP, VIP | NPBWR1 59/4885KISS1R 157/4885OPRD1 3405/4885 |
| US-11396533-B2 | Process for the manufacture of GLP-1 analogues | GLP1R, IAPP, VIP | NPBWR1 59/4885KISS1R 157/4885OPRD1 3405/4885 |
| US-20240247042-A1 | GLUCAGON LIKE PEPTIDE COMPOUNDS | GLP1R, IAPP, GPR119 | NPBWR1 198/4885KISS1R 564/4885OPRD1 3212/4885 |
| US-20250206798-A1 | INSULIN CONJUGATES | IAPP, INSR, IGF1R | NPBWR1 739/4885KISS1R 173/4885OPRD1 4779/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.